Lilly Profit Beats Analysts’ Estimates as Cymbalta Sales Rise

Lilly Profit Beats Analysts’ Estimates as Cymbalta Sales Rise

JB Reed/Bloomberg

Eli Lilly & Co. is in the process of cutting hundreds of jobs as it prepares for the loss of patent protection on its top-seller Cymbalta at the end of the year. Photographer: